Alkasa Lifesciences Limited (ALF Ltd.), a public limited company, is a healthcare conglomerate, with its operations in four major verticals-Pharmaceutical Manufacturing, Medical Equipment, Wellness and Nutrition Products

Alkasa Lifesciences Limited (ALF Ltd.), a public limited company, is a healthcare conglomerate, with its operations in four major verticals-Pharmaceutical Manufacturing, Medical Equipment, Wellness and Nutrition Products and Diagnostics. ALF Ltd.'s, 75-year-old traditional Pharma business, is the backbone of the company. However, over the past few years, the company has expanded its operations through the Wellness and Nutrition division which has experienced rapid growth, driven by rising demand for preventive health products. Evercare Path Labs, a wholly owned subsidiary, is yet another diversification venture of ALF Ltd. which though is a high-growth unit but lacks synergy with the other pharma activities. The stakeholders have raised concerns that the company's diversified structure might dilute the overall performance and valuation of the company. Investing too much in expansion without a clear strategy can make the business vulnerable to market changes or operational failures, increasing the risk of substantial financial losses. Hence, they suggest to shed off the non-core units to focus on core areas. But the management feels a strong sense of ownership and pride over the units they have personally developed and nurtured, making it difficult to let them go. Hence the suggestion of divestiture is completely unacceptable to them. In response to this deadlock, the Board of Directors have hired Mr. Agrim Basu as their Strategic advisor for exploring strategic options to unlock the value of the high-growth divisions and improving focus on its core pharmaceutical operations. Mr. Basu has suggested a scheme explaining that the company may opt for a divestiture, capital restructuring, buyback and acquisitions/mergers as part of a strategic initiative to enhance shareholder value and optimize operational focus. Together, these steps will reflect proactive financial management and strategic clarity, positioning the company for sustainable long-term growth while maintaining investor trust and market competitiveness. Convinced with the suggestions of Mr. Basu, the following scheme is formulated : Divest Evercare Path Labs or Separate Evercare Path Labs for value unlocking (via carve-out) as diagnostics business no longer aligns with ALF Ltd.'s long-term strategic direction. Use proceeds from above step to repay high-interest debt of ₹ 500 crore to improve debt-equity ratio and further support financial stability. Further, a buyback of shares under Section 68 of the Companies Act, 2013, utilizing ₹ 800 crores of the proceeds. Improved EPS from buyback may help in market perception during future takeover bids, potentially reducing acquisition cost. With remaining proceeds and a stronger financial position post-buyback, ALF Ltd. will be all set for mergers/acquisition. The process of merging with another company or acquiring a company is complex. In addition to the legal ramifications, companies must be aware of the potential tax implications as well as ensuring that the terms of the deal benefit both parties. ALF Ltd. has created a team of strategic advisors, lawyers and professionals to negotiate on their behalf in order to obtain the best possible deal within the framework of the applicable laws. After rounds of deliberations and due diligence of various options proposed by the special team, ALF Ltd. selected Debonya Limited, for acquisition, as this was the company which could offer ALF Ltd., a growth potential to expand the market share, gain access to new R&D and automation processes, and above all achieve operational synergies in its core pharma manufacturing sector. Eventually ALF Ltd. acquired Debonya Limited in a business combination on 1st April, 2025. Based on the above facts, answer the following questions : Stakeholders suggest that instead of diverting capital and effort into many different areas, the company should consolidate its resources and management focus more effectively into strengthening its core competencies whereas management does not want to leave their high growth hard earned units. As their strategic advisor, you could remove this deadlock between management and stakeholders by explaining them the difference between full divestiture and an equity carve-out. Which one out of the above did you suggest to unlock the value of ALF's high growth but non-core business unit—Evercare Path Labs, so that the decision is acceptable to both—stakeholders and management. Also explain how did you present the rest of your strategy to both of them to gain approval for debt restructuring, buyback and acquisition too.